News & Updates
Excerpt from the Press Release: LA JOLLA, Calif., June 05, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent…
Read More
Excerpt from the Press Release: EMERYVILLE, Calif.–(BUSINESS WIRE)–Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, recently presented a poster on NTX-472, its new preclinical drug candidate for B cell lymphoma, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Monoclonal antibody immunotherapies…
Read More
100% of treated patients in Arm 1 achieved virologic response by Week 28 Most patients also achieved ALT normalization and composite response BJT-778 was well tolerated across all arms at doses up to 900mg Excerpt from the Press Release: SAN MATEO, Calif., June 05, 2024 (GLOBE NEWSWIRE) — Bluejay Therapeutics, a private clinical-stage biopharmaceutical company…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the initiation of the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety…
Read More
Excerpt from the Press Release: BROOKLINE, Mass.–(BUSINESS WIRE)–Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, today announced that the first two patients with metastatic breast cancer were treated with BTX-A51, a multi-specific kinase inhibitor of casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company presented clinical data and preclinical data of bexotegrast (PLN-74809) this…
Read More
– In a multiple-ascending dose (MAD) study in patients with asthma, up to 54% reduction in fractional exhaled nitric oxide concentration (FENO) was observed with administration of verekitug, with treatment effects sustained up to 24 weeks after last dose – – Verekitug displayed a favorable safety and tolerability profile without evidence of clinically meaningful immunogenicity…
Read More
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting Additional KT-621 preclinical data was also featured in a poster presentation at Digestive Disease Week KT-621 expected to start Phase 1 in the second half of 2024,with Phase…
Read More
CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting Initial data expected by year-end 2024 Excerpt from the Press Release: PHILADELPHIA, May 16, 2024 /PRNewswire/ — Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?